Severe coronavirus disease 2019 causes multi-organ dysfunction with significant morbidity and mortality. Mounting evidence implicates maladaptive over-activation of innate immune pathways such as the complement cascade as well as endothelial dysfunction as significant contributors to disease progression. We review the complement pathways, the effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on these pathways, and promising therapeutic targets in clinical trials.

Original languageEnglish
Article number2188
JournalJournal of Clinical Medicine
Issue number10
StatePublished - 2 May 2021


  • COVID-19
  • Complement inhibitor
  • Complement pathway
  • Lectin pathway
  • Mannose-associated serine protease inhibitor
  • SARS-CoV-2


Dive into the research topics of 'Targeting the complement cascade in the pathophysiology of covid-19 disease'. Together they form a unique fingerprint.

Cite this